Comparative Pharmacology
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus PYRIMETHAMINE SULFADOXINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROQUINE PHOSPHATE versus PYRIMETHAMINE SULFADOXINE.
CHLOROQUINE PHOSPHATE vs Pyrimethamine-Sulfadoxine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
Pyrimethamine inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis. Sulfadoxine inhibits dihydropteroate synthase, blocking folate synthesis. Sequential blockade of folate metabolism.
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Pyrimethamine 25 mg plus sulfadoxine 500 mg per tablet; typical adult dose for acute uncomplicated malaria is 3 tablets (pyrimethamine 75 mg, sulfadoxine 1500 mg) orally as a single dose. For toxoplasmosis in immunocompromised patients: loading dose pyrimethamine 200 mg orally once, then pyrimethamine 50-75 mg orally once daily plus sulfadoxine 1000-1500 mg orally once daily (dosing based on sulfadoxine component) for 4-6 weeks, then reduce to half.
None Documented
None Documented
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
Pyrimethamine: ~80-120 hours; Sulfadoxine: ~100-200 hours. Long half-lives allow single-dose therapy for malaria.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Renal: ~60% unchanged sulfadoxine, ~5% unchanged pyrimethamine; fecal: ~10% pyrimethamine. Biliary excretion minimal.
Category C
Category C
Antimalarial
Antimalarial